Pictured: Woman grasping her stomach in pain/iStock, Doucefleur The use of glucagon-like peptide 1 (GLP-1) agonists for weight loss, such as Novo Nordisks Ozempic and Wegovy, is associated with the risk of gastrointestinal adverse events, according to a study published Thursday in the medical journal JAMA
[PubMed Central ID: PMC5544618]
Semaglutide has been the subject of various studies highlighting its efficacy in promoting weight reduction
Its important to consider the risks and benefits of any treatment before deciding whether to pursue it
The recent urbanization and changes in lifestyles, eating habits, and other factors have exposed the global population to a variety of chronic diseases
La sntesis tiene lugar en el hgado, los riones y el cerebro